Healthcare Equipment and Supplies
Company Overview of C2 Therapeutics, Inc.
C2 Therapeutics, Inc., a medical device company, develops and commercializes Coldplay CryoBalloon, a focal ablation system for the endoscopic ablation of Barrett’s esophagus. It serves patients in Europe. The company was incorporated in 2007 and is based in Redwood City, California. As of January 10, 2017, C2 Therapeutics, Inc. operates as a subsidiary of PENTAX Medical Company.
303 Convention Way
Redwood City, CA 94063
Founded in 2007
Key Executives for C2 Therapeutics, Inc.
Vice President of Finance
Vice-President of Regulatory and Quality
Compensation as of Fiscal Year 2016.
C2 Therapeutics, Inc. Key Developments
C2 Therapeutics Announces Initiation of Coldplay III Trial Validating the C2 CryoBalloon™ Focal Ablation System for Primary Treatment of Barrett’s Esophagus
Jun 7 16
C2 Therapeutics announced the initiation of its Coldplay III trial with treatment of the first patient at University Hospitals in northeast Ohio. The patient was treated with the C2 CryoBalloon Focal Ablation System by John Dumot, D.O., Director, Digestive Health Institute, University Hospitals, commencing the clinical trial to validate the efficacy and safety of the system in patients with Barrett's esophagus. The prospective, multi-center, non-randomized, single arm study (NCT02514525) will enroll 60 patients with multifocal Barrett's esophagus less than 6 cm in full circumferential size and no previous treatment. The primary outcomes measure is eradication of any grade Barrett's esophagus at 12 months post-treatment. This will be evaluated by using the Seattle protocol surveillance strategy that involves targeted biopsies of mucosal abnormalities, plus four-quadrant biopsies obtained at every 1 cm. The presence of Barrett's esophagus and degree of disease will be confirmed by histopathologic analysis. Participating trial centers include: Columbia University Medical Center in New York, New York; Geisinger Medical Center in Danville, Pennsylvania; John Hopkins Medicine in Baltimore, Maryland; Temple University Hospital in Philadelphia, Pennsylvania; University Hospitals Ahuja Medical Center in Beachwood, Ohio; University of North Carolina in Chapel Hill, North Carolina; and University of Rochester Medical Center in Rochester, New York.
C2 Therapeutics Announces Leadership Team Expansion
Jan 26 16
C2 Therapeutics announced the appointment of five new members to its leadership team. These individuals join an existing team of seasoned leaders who will be instrumental in enabling C2 Therapeutics' continued development and growth. Jennifer Halsey is a senior executive in strategy and finance, focused on capital-efficient growth and partnerships for promising medical technology companies. She works collaboratively with entrepreneurs and shareholders to determine the optimal path for value creation, and she helps facilitate successful partnerships to commercialize innovative new products. Ryan Brennan is senior-level professional with more than 14 years of sales and sales management experience in the medical device industry. He has worked with leading companies to bring advanced technology to physicians, previously serving in key roles at Covidien, BARRX Medical and Johnson & Johnson. Lisa Bichsel has more than 35 years’ experience in healthcare marketing – managing all aspects of product and service marketing within the fields of gastroenterology (including BARRX Medical, also in the endoscopic ablation market), neurosurgery, orthopedics, emergency medicine, ophthalmology, podiatry, radiology, and patient financial services. Quentin Manley is a sales and marketing executive in the healthcare sector, with key experience in medical devices and technology. He has extensive experience creating high performing teams, devising successful go-to-market strategies, driving business models and surpassing growth and sales targets. Linda is a financial professional with more than 35 years of experience in both the public and private sectors. Linda most recently served as director of finance for OptiMedica Corporation, a venture-backed company in ophthalmology that was successfully acquired by Abbott Labs in 2013.
C2 Therapeutics Receives FDA 510(K) Clearance for the Coldplay Cryoballoon Full and Swipe Ablation Systems
Jul 29 15
C2 Therapeutics announced US Food and Drug Administration (FDA) 510(k) clearance for the Coldplay Cryoballoon™ Full Ablation System and the Coldplay Cryoballoon™ Swipe Ablation System. Barrett’s Esophagus develops as a result of chronic injury from gastroesophageal reflux disease (GERD). Over time, the normal esophageal lining is replaced with abnormal cells (Barrett’s Esophagus), putting patients at greater risk of developing cancer of the esophagus.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 10, 2017